Former Stericycle Finance Director Charged For Alleged Bribes
By Ben Glickman
A former finance director for the Latin America division of Stericycle was charged for his alleged role in a $10 million bribe scheme.
The Justice Department alleged Abraham Cigarroa Cervantes, 51, and others had helped make hundreds of bribe payments to officials in Brazil, Mexico and Argentina to secure business and gain an advantage for the waste-management company.
Stericycle in 2022 admitted to bribing officials in the three countries. It entered a three-year deferred prosecution agreement and agreed to pay more than $84 million to various authorities.
Cigarroa and Stericycle couldn't immediately be reached for comment.
The indictment of Cigarroa was returned Tuesday by a federal grand jury in the Southern District of Florida.
Cigarroa and other employees allegedly made payments, typically in cash, to officials, then maintained false books and records in order to post the bribe payments as legitimate expenses.
The Justice Department said Cigarroa would face a maximum penalty of five years in prison for each of the two counts charged if he is convicted.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 19, 2024 19:14 ET (23:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks